BTIG raised the firm’s price target on Liquidia to $29 from $18 and keeps a Buy rating on the shares. The company’s winning the ‘793 IPR appeal is the most de-risking legal event on YUTREPIA’s path to freedom to operate, the analyst tells investors in a research note. From here, Liquidia should request that the current injunction approved by Justice Andrews is to be removed, since it was supported by the ‘793 patent, the firm states, adding that it expects YUTREPIA to emerge as the preferred DPI treprostinil Tx option in PAH and PH-ILD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LQDA:
- U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
- Liquidia director Manning buys 279,330 common shares
- Liquidia prices 3.49M shares at $7.16 in underwritten public offering
- Liquidia Announces Pricing of Public Offering of Common Stock
- Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
